

**Applicant:** Spark Therapeutics Inc.  
**Address:** 3737 Market St  
**City, State, and Zip Code:** Philadelphia, PA 19104  
**U.S. License Number:** 2056  
**FEI Number:** 3011194531

Name/Address	FEI number	DUNS number	Inspection/waiver	Justification /Results
Drug Substance Manufacturing and Testing  Spark Therapeutics Inc. 3737 Market St Philadelphia, PA 19104 USA	3011194531	079498241	Pre-License Inspection <i>(refer to the attached FACTS endorsement)</i>	CBER August 2-25, 2017 VAI
<div style="text-align: center; font-size: 48px; font-weight: bold;">(b) (4)</div>			Waived <i>(refer to the attached inspection wavier memo)</i>	CBER (b) (4) VAI
			Waived <i>(refer to the attached inspection wavier memo)</i>	BIMOE (b) (4) VAI
			Waived <i>(refer to the attached inspection wavier memo)</i>	IOG (b) (4) NAI
			Waived <i>(refer to the attached inspection wavier memo)</i>	ORA (MIN-DO) (b) (4) VAI

**Short Summary:**

A Biological License Application (BLA) is submitted for voretigene neparvovec (genetically engineered virus) with a proprietary name of "Luxturna". This BLA is designated as a breakthrough BLA for priority review. Voretigene neparvovec (AAV2-hRPE65v2) is an adeno-associated viral type 2 (AAV2) gene therapy vector (gene therapy product) and proposed for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy. This product is administered via subretinal Injection.

There are no ongoing or pending investigations or compliance actions with respect to the above facilities or their product(s). Therefore, the Office of Compliance and Biologics Quality, Division of Case Management does not object to the approval of this original submission.

***Marc A. Alston, M.S.***

***Consumer Safety Officer***

***CBER/OCBQ/DCM/BDDEB***

**From:** Ballica, Rabia

**Sent:** Monday, November 20, 2017 3:20 PM

**To:** CBER CompliCheck <complcheck@fda.hhs.gov>

**Cc:** Morris, Nevitt <Nevitt.Morris@fda.hhs.gov>; Renshaw, Carolyn <Carolyn.Renshaw@fda.hhs.gov>

**Subject:** Compliance Status Check - BLA STN 125610/0

**ESTABLISHMENT EVALUATION REQUEST**

**Date:** 11/20/2017

**Request Type (Check One):** Original  Follow-up

**Reviewer's Name, Division, Mail Code, Phone Number:** Rabia Ballica,  
CBER/OCBQ/DMPQ/Branch I

W071-RM6040, HFM-675, Phone: 240-402-9379

**Application Number and Type:** BLA STN 125610/0

**Applicant:** Spark Therapeutics Inc.

**Address:** 3737 Market St

**City, State, and Zip Code:** Philadelphia, PA 19104

**U.S. License Number:** 2056

**FEI Number:** 3011194531

**Short Summary:**

A Biological License Application (BLA) is submitted for voretigene neparvovec (genetically engineered virus) with a proprietary name of “Luxturna”. This BLA is designated as a breakthrough BLA for priority review.

Voretigene neparvovec (AAV2-hRPE65v2) is an adeno-associated viral type 2 (AAV2) gene therapy vector (gene therapy product) and proposed for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy. This product is administered via subretinal Injection.

CBER conducted a pre-license inspection (PLI) of Spark Therapeutics Inc. (FEI# 3011194531) from August 21 - 25, 2017 for voretigene neparvovec drug substance manufacturing. This manufacturing facility is located at 3737 Market St, Philadelphia, PA 19104. This inspection was classified as voluntary action indicated (VAI). *Refer to the attached FACTS Endorsement.*

(b) (4) is responsible for manufacturing voretigene neparvovec drug product and its diluent and performing sterility testing at release. (b) (4) is located at (b) (4). The inspection of this facility is waived based on the information provided in the BLA and previous FDA inspection history. *Refer to the attached wavier memo.*

Contract testing facilities (in addition to the drug substance and drug product manufacturing facilities) are listed in the table below. *Refer to the attached inspection wavier memos for the contract testing facilities.*

Please provide information on the current compliance/cGMP status of the following manufacturing and testing sites **by December 1, 2017.**

**Table:** Manufacturing and testing facilities

Name/Address	FEI number	DUNS number	Inspection/waiver	Justification /Results
Drug Substance Manufacturing and Testing  Spark Therapeutics Inc. 3737 Market St Philadelphia, PA 19104 USA	3011194531	079498241	Pre-License Inspection <i>(refer to the attached FACTS endorsement)</i>	CBER August 2-25, 2017 VAI
<b>(b) (4)</b>			Waived <i>(refer to the attached inspection wavier memo)</i>	CBER (b) (4) VAI

<span style="font-size: 48pt;">(b) (4)</span>	Waived <i>(refer to the attached inspection wavier memo)</i>	BIMOE (b) (4) VAI
	Waived <i>(refer to the attached inspection wavier memo)</i>	IOG (b) (4) NAI
	Waived <i>(refer to the attached inspection wavier memo)</i>	ORA (MIN-DO) (b) (4) VAI

VAI: Voluntary Action Indicated; NAI: No Action indicated

IOG: International Operations Group; BIMOE: Division of Bioresearch Monitoring Operations East

Let me know if you have any questions. Thanks

Rabia Ballica, PhD

*Biologist Regulatory Reviewer*

*FDA/CBER/OCBQ/DMPQ/MRBI*

*10903 New Hampshire Ave*

*W071-RM6040*

*Silver Spring, MD 20993-0002*

*Phone: 240-402-9379*